Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial (Q38601785)
Jump to navigation
Jump to search
scientific article published on 25 August 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial |
scientific article published on 25 August 2017 |
Statements
1 reference
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial (English)
1 reference
Peter Libby
1 reference
Paul M Ridker
1 reference
Robert J Glynn
1 reference
Jean G MacFadyen
1 reference
Tom Thuren
1 reference
CANTOS Trial Group
1 reference
Brendan M Everett
1 reference
25 August 2017
1 reference
1 reference
Identifiers
1 reference